Slørdahl KS, Puco K, Falk RS, Dyvik I, Brabrand S, Niehusmann P, Steinskog ESS, Blix ES, Flobak Å, Oppedal IA, Meltzer S, Torkildsen CF, Blakstad H, Lindemann K, Smeland S, Amundsen A, Taskén K, Helland Å, InPred Consortium (2026) Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial Acta Oncol, 65, 90-96 DOI 10.2340/1651-226X.2026.45086, PubMed 41664938 Ystgaard MF, Myklebust TÅ, Smeby J, Larsen IK, Guren TK, Kure EH, Tveit KM, Glimelius B, Guren MG, Hamfjord J (2024) Early-onset colorectal cancer incidence in Norway: a national registry-based study (1993-2022) analyzing subsite and morphology trends ESMO Gastrointest Oncol, 7, 100065 DOI 10.1016/j.esmogo.2024.100065, PubMed 41646485 Girard N, Bar J, Baas P, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido Lopez P, Gregorc V, Haakensen VD, Hiltermann TJN, Kao S, McDonald F, Mornex F, Moskovitz M, Peters S, Siva S, Solomon B, Qiao Y, Anand S, Chander P, Shcherbakova T, Diaz Perez I, Filippi AR (2026) Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC ESMO Open, 11 (2), 106070 (in press) DOI 10.1016/j.esmoop.2026.106070, PubMed 41643268
